Publications by authors named "R Kabarriti"
Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT).
Int J Radiat Oncol Biol Phys
January 2025
Background: Standard radiotherapy (RT) for locally advanced NSCLC (LA-NSCLC) employs a uniform dose of approximately 60 Gy. Recent trials demonstrated that radiotherapy dose escalation may not improve outcomes and may cause added toxicity. XXX previously performed a single-arm trial testing a personalized, risk-adapted, and de-intensified RT strategy.
View Article and Find Full Text PDFBackground: The incidence and mortality of anal squamous cell carcinoma (ASCC) are rising, with greater than 80% of cases linked to human papillomavirus (HPV), primarily HPV16. Post-treatment surveillance can be challenging due to the limitations of anoscopy, digital anal rectal exam (DARE), and imaging. Plasma tumor tissue modified viral (TTMV)-HPV DNA has shown strong sensitivity, specificity, and predictive value in detecting the recurrence of HPV-driven oropharyngeal cancer.
View Article and Find Full Text PDFArticle Synopsis
- Head and neck cancer (HNC) is a growing health issue in Rwanda, with a study analyzing data from 1001 patients revealing that 82% had squamous cell carcinoma and a mean age of diagnosis at 51.1 years, predominantly in males.
- The study utilized p16 immunohistochemistry to assess HPV prevalence, finding that 22% of cases were p16-positive, with 19% testing positive for HPV, particularly HPV16.
- It concluded that there is an urgent need for improved cancer testing and data collection in Rwanda to better understand and combat HNC, especially focusing on oropharyngeal cases and associated risk factors.
Ultrahigh-dose-rate therapy, also known as FLASH radiotherapy (RT), is an emerging technique that is garnering significant interest in cancer treatment due to its potential to revolutionize therapy. This method can achieve comparable tumor control to conventional-dose-rate RT while offering the enhanced protection of normal tissue through the FLASH-sparing effect. This innovative technique has demonstrated promising results in preclinical studies involving animals and cell lines.
View Article and Find Full Text PDFArticle Synopsis
- - Delays in starting treatment for laryngeal squamous cell carcinoma (LSCC) may lead to worse survival outcomes, potentially due to faster tumor growth or spreading of the disease.
- - A study of 105 LSCC patients found that tumors growing faster than 0.036 mL/day are linked to lower overall survival rates, while faster growth rates beyond 0.082 mL/day are heavily associated with higher chances of recurrence.
- - Evaluating tumor growth rates during treatment delays could help identify patients who may need more aggressive treatment options to improve their outcomes.